文献速递皮肤肿瘤自身免疫性与大疱性皮肤病

研究技术简明指南:CAR-T细胞疗法

Research Techniques Made Simple: CAR T-Cell Therapy.
PubMed 文献 · J Invest Dermatol · 2018-09-19

本文介绍嵌合抗原受体(CAR)T细胞疗法的基本原理:将患者T细胞基因工程化表达抗原特异性抗体片段与激活型胞质T细胞信号结构域融合,经体外激活和遗传修饰后回输,选择性破坏携带靶抗原的细胞。抗CD19 CAR-T产品已获美国食品药品监督管理局批准用于难治性淋巴瘤,初步研究显示对黑色素瘤和寻常型天疱疮致病B细胞有效,但存在细胞因子释放综合征高风险,可表现为皮肤表现。

要点

  • CAR-T疗法通过基因工程改造患者T细胞,使其表达抗原特异性抗体片段与激活型T细胞信号结构域融合蛋白。
  • 靶向CD19的CAR-T细胞在难治性淋巴瘤中显示显著临床疗效,两个抗CD19 CAR-T产品已获美国食品药品监督管理局批准。
  • 初步研究显示CAR-T细胞对黑色素瘤和寻常型天疱疮致病B细胞有疗效,但当前临床CAR-T治疗存在细胞因子释放综合征高风险。

核心结论

  • CAR-T细胞疗法在癌症和自身免疫病治疗中前景广阔,但当前临床CAR-T治疗携带细胞因子释放综合征高风险,皮肤科医生需认识其潜在皮肤并发症。

研究设计与样本

  • 本文为研究技术简明指南,介绍CAR-T细胞疗法的原理、临床应用及皮肤科相关意义。

主要发现

  • 抗CD19 CAR-T细胞在难治性淋巴瘤治疗中显示显著临床疗效,两个抗CD19 CAR-T产品近期获美国食品药品监督管理局批准。
  • 初步研究显示CAR-T细胞靶向黑色素瘤细胞和寻常型天疱疮致病B细胞有效。
  • 当前临床CAR-T治疗携带细胞因子释放综合征高风险,这是一种可能致命的全身炎症反应,可表现为皮肤表现。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor (CAR) and chimeric autoantibody receptor T-cell therapy hold great promise in the treatment of cancer and autoimmune disease, respectively. This powerful technique involves genetically engineering T lymphocytes to enable selective destruction of disease-causing cells. In the current approach, a patient's T cells are genetically engineered to express an antigen-specific antibody fragment fused to activating cytoplasmic T-cell signaling domains. After ex vivo activation and genetic modification of a patient's own T cells, the individually tailored CAR T cells are then infused into the patient for the selective destruction of cells bearing the targeted antigen. CAR T cells directed against the CD19 antigen expressed on B lymphoma cells have shown remarkable clinical efficacy in the treatment of refractory lymphoma, with two anti-CD19 CAR-T products recently gaining approval from the US Food and Drug Administration. For dermatological disease, preliminary studies have shown efficacy of CAR T cells in targeting melanoma cells and the pathogenic B cells in pemphigus vulgaris. Despite its great promise, current clinical CAR T-cell (or CAR-T) therapy carries a high risk of cytokine release syndrome, a potentially fatal systemic inflammatory response that can be manifest in cutaneous findings. For the dermatologist, the rapid clinical emergence of CAR-T therapy promises to treat and cure a variety of dermatological conditions, but it also requires an astute awareness of potential cutaneous complications in the increasing number of patients undergoing CAR-T therapy.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Siddiqi HF, Staser KW, Nambudiri VE, et al. Research Techniques Made Simple: CAR T-Cell Therapy. J Invest Dermatol. 2018. PMID: 30243656. doi:10.1016/j.jid.2018.09.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。